About
Our mission is to establish the scaffold technology as gold standard for cancer drug development and develop own successful treatments for aggressive cancer.
Vision & Mission
Cancer remains a major health issue through-out the world and rates are increasing.
Despite the progress that has been made there is a high unmet need to cure aggressive forms of cancer. Our vision is to cure cancer by generating precision medicin
Our mission is to establish the scaffold technology as gold standard for cancer drug development and develop own successful treatments for aggressive cancer.
About ISCAFFPHARMA
Iscaffpharma is a Bio-Tech company focusing on developing better treatments of aggressive cancers. It is based on research by professor Göran Landberg and associate professor Anders Ståhlberg at Sahlgrenska Cancer Center. The research has documented that the scaffold (environment) of the tumour impacts the aggressiveness of cancers. We have developed this technology into a cost-effective platform to improve success rate in clinical development of treatments for aggressive cancer.
We do this by providing patient derived and synthetic scaffolds mimicking the human tumour microenvironment as a platform for research and development. The 3D scaffolds will verify the efficacy of drug treatment and provide high quality data to support decision on which drugs to move into clinical trials. As a further mean of increasing the quality of data, Iscaffpharma also offers validation of 3D synthetic scaffold results in human scaffolds.
Substantial R&D funding has been received with Vinnova grant (45 million Skr) – challenge driven innovation (UDI 3). Initial collaboration agreements with cancer companies are established. The research has generated a patent and submission of additional patents is ongoing.
More than 25 Phd’s in research at Sahlgrenska Cancer Center
Management team
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Sara Malcus – Chairman of the board
Sara Malcus has more than 15 years of experience from the pharmaceutical and biotech industries. She is the former CEO and co-founder of MetaboGen, a microbiome company (acquired by BioGaia) and has served on the boards of Vicore Pharma and Oncorena. Sara has a PhD in Inflammation Medicine and extensive experience in the management of small companies in the life science sector, from positions in business development and investment management, both at Astra Zeneca and GU Ventures.
Göran Landberg – CMO
Göran Landberg is a professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Göran Landberg – CMO
Göran Landberg is a professor and senior consultant in pathology and the principal investigator of a large research group at the Sahlgrenska Cancer Center at the University of Gothenburg. His research interest is focused on molecular pathology based translational projects with a goal to develop novel diagnostic and treatment principles for cancer patients better targeting true malignant features by understanding key tumour biological issues and properties including the tumour microenvironment.
Anders Ståhlberg – CTO
Anders Ståhlberg, Associate Professor, is working as principal investigator at Sahlgrenska Cancer Center, University of Gothenburg and Clinical Pathology and Genetics, Sahlgrenska University Hospital. His research is focused on breast cancer and sarcomas, including childhood sarcomas. Anders has developed several molecular approaches for gene expression profiling and mutation analysis, especially at the single-cell and single-molecule level resulting in several patents and products.
Anders Ståhlberg – CTO
Anders Ståhlberg, Associate Professor, is working as principal investigator at Sahlgrenska Cancer Center, University of Gothenburg and Clinical Pathology and Genetics, Sahlgrenska University Hospital. His research is focused on breast cancer and sarcomas, including childhood sarcomas. Anders has developed several molecular approaches for gene expression profiling and mutation analysis, especially at the single-cell and single-molecule level resulting in several patents and products.
Charlotta Blom – Board member
Charlotta Blom has an extensive background as a researcher in both academia and the biotech industry. She is currently a senior intellectual property (IP) business consultant at Synergon where she works closely with Iscaff Pharma to develop and maintain strategies to protect new ideas and inventions. In this position, her focus is to identify, develop, and maintain commercially relevant IP protection by handling the strategic management of, for instance, Iscaff Pharma’s patent and trademark portfolios. Charlotta has been handling Iscaff Pharma’s IP matters over the last couple of years in order to facilitate the increasing value of the company’s IP rights.
Charlotta Blom – Board member
Charlotta Blom has an extensive background as a researcher in both academia and the biotech industry. She is currently a senior intellectual property (IP) business consultant at Synergon where she works closely with Iscaff Pharma to develop and maintain strategies to protect new ideas and inventions. In this position, her focus is to identify, develop, and maintain commercially relevant IP protection by handling the strategic management of, for instance, Iscaff Pharma’s patent and trademark portfolios. Charlotta has been handling Iscaff Pharma’s IP matters over the last couple of years in order to facilitate the increasing value of the company’s IP rights.
Per Setterberg – CEO
Marketing professional with a Bachelor of economy from School of business Gothenburg University and Bachelor of law from Lunds University. More than 20 years of sales and marketing experience in Life Science. Working with strategy and tactics as board member all the way to operational marketing and sales, focusing in pharmaceutical and med tech . Per strongly believes in the added value for all, from business, society and last but not least the patient.
Per Setterberg – CBO
Marketing professional with a Bachelor of economy from School of business Gothenburg University and Bachelor of law from Lunds University. More than 20 years of sales and marketing experience in Life Science. Working with strategy and tactics as board member all the way to operational marketing and sales, focusing in pharmaceutical and med tech . Per strongly believes in the added value for all, from business, society and last but not least the patient.
Partners, Collaborators and Investors
Iscaffpharma is part of UDI3 challenge driven innovation supported by Vinnova. Our partners are:
